Switzerland · Delayed Price · Currency is CHF Cosmo Pharmaceuticals Company Description
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic.
It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17α-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system.
The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited.
Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
| Country | Netherlands |
| Founded | 1997 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 322 |
| CEO | Giovanni Di Napoli |
Contact Details
Address: Riverside II Dublin, 2 Ireland | |
| Phone | 353 1 817 0370 |
| Website | cosmopharma.com |
Stock Details
| Ticker Symbol | COPN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | NL0011832936 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Giovanni Di Napoli | Chief Executive Officer and Director |
| Alessandro E. Della Cha LL.M | Non Executive Chairman |
| Mauro Severino Ajani | Founder and Non-Executive Director |
| Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer and Executive Director |
| Svetlana Sigalova | Chief Financial Officer |
| Marco Lecchi | Chief Operating Officer |
| Davide Malavasi | Qualified Person and Technical Director |
| Luigi Longo | Chief Scientific Officer |
| Federico Sommariva | Chief Legal Counsel |
| Roberto Villa | Chief Manufacturing Officer |